Tailored DNA vaccine sparks immune response against glioblastoma in early trial

A phase 1 trial at Siteman Cancer Center shows a personalized neoantigen DNA vaccine (GNOS-PV01) for glioblastoma is safe and elicits robust immune responses; among nine patients, about two-thirds had no progression at six months and two-thirds were alive at one year, including a long-term recurrence-free survivor, indicating potential benefit and the need for larger trials.